Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Open ADVB dashboard ↗Personalis, Inc. Common Stock
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Open PSNL dashboard ↗